Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Breast Neoplasms 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Recurrent Malignant Solid Neoplasm 1Non-hematologic Malignancy 1Neoplasms 1Multiple Myeloma 1Meningeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma, Large-Cell, Anaplastic 1Hematologic Neoplasms 1Gliosarcoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Nonhematological Neoplasms 1Adenoma, Islet Cell 1

Interventions

sapanisertib 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrent Malignant Solid Neoplasm × sapanisertib × Clear all
NCT03430882 2022-06-21

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
35 enrolled
Other solid neoplasm

Recurrent Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡